ロード中...
Current Status: Site-Specific Antibody Drug Conjugates
Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as div...
保存先:
| 出版年: | J Clin Immunol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891387/ https://ncbi.nlm.nih.gov/pubmed/27003914 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-016-0265-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|